We study diagnostic tests and treatments to determine which are best and safest for patients.
We study risk factors for developing vascular disease, including genes, biomarkers, and lifestyle factors.
We use modern “omic” technologies to study the changes in metabolites, proteins and imaging measures that occur when someone develops a pulmonary embolism (PE) or deep vein thrombosis (DVT).
The CVE coordinates data collection and analysis for the MGH Pulmonary Embolism Response Team (PERT).
The Therapeutic Heparinization and Antithrombin Normalization Observational Study (THANOS).
The ThRombosis ExclUsion STudy (TRUST) is an international, multicenter clinical trial of a new D-dimer assay.
A multi-center study of >3000 ED patients demonstrating the safety of outpatient PE treatment.
The REgistry of potential COVID-19 in emERgency care (RECOVER) is the largest multicenter US registry of ED patients tested for SARS-CoV-2.
The INternational VENous Thrombosis Network is the world’s largest consortium of genetic epidemiology studies of VTE.
Exploring how Dual Energy CT (DECT) imaging can improve the diagnosis of PE.
The Safe Pulmonary Embolism Emergency Department Discharge (SPEED-D) study.
Biorepository of blood samples from patients diagnosed with acute PE.
RECOVER CDC is an ongoing, multi-center registry of emergency department patients tested for possible SARS-CoV-2 infection, performed in collaboration with the US CDC.